US Federal House Bill HB8269

US Federal 2025-2026 Regular Session

• Introduced: 4/14/26
• Refer: 4/14/26

Caption

CLEAR LABELS Act Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act

Impact

If enacted, HB8269 would have a significant impact on state laws related to drug distribution and consumer health protections. By requiring drug labels to clearly identify the original manufacturer and the supply chain information, the bill promotes greater accountability within the pharmaceutical industry. This change is expected to facilitate better tracking of drug products and assist in the identification of sources in the event of a recall or safety issue. Additionally, it aims to bolster consumer confidence in the medications they use.

Summary

House Bill 8269, known as the CLEAR LABELS Act, seeks to amend the Federal Food, Drug, and Cosmetic Act by introducing new requirements for drug labeling. The primary focus of this legislation is to mandate that labeling for finished drug products include specific information about the original manufacturer and supply chain details. This act aims to enhance transparency in pharmaceutical labeling, allowing consumers and healthcare providers to make more informed decisions regarding medications.

Contention

The bill has generated discussion among legislators regarding the potential trade-offs of increased transparency versus regulatory burden on pharmaceutical manufacturers. While proponents argue that such transparency is essential for consumer safety and trust, some critics have raised concerns about the feasibility of implementing these requirements and the associated costs for manufacturers. They fear that smaller firms, in particular, might struggle to comply with these new regulations, which could ultimately hamper competition in the marketplace.